Document made available to the pharmacist to communicate a drug interaction to the doctor.DOWNLOAD
Glecaprevir / Pibrentasvir may inhibit hepatic transports OATP1B1/B3 and BCRP and increase plasma concentration of Rosuvastatin.
P-gp and BCRP; OATP1B1/3 (glecaprevir)
P-gp, BCRP, OATP1B1/3; 3A4, 1A2 and UGT 1A1 (weak probably without clinical consequences)
OATP1B1, OATP1B3 and BCRP
Possible increased risk of HMG CoA inhibitor toxicity.
Increased risk of myopathy and rhabdomyolysis.
Use this combination with caution.
Start with a small dosage. Monitor closely for signs and symptoms of toxicity and adjust dosage as a function of efficacy and tolerance.
Canadian product monograph does not recommend more than 5 mg per day.
The US product monograph recommends instead a maximum dose of 10 mg daily.
Symptoms of toxicity associated with hypolipidemic agents : gastrointestinal effects, fatigue and muscular weaknesses, myalgias, muscular cramps, myopathies, rhabdomyolysis and myoglobinuria leading to renal insufficiency.
|+ 462% (5.6x)|
|+ 115% (2.2x)|